This invention provides a series of novel hetera-aliphatic carboxamides of formula I in which the group >Z-Y-X< is selected from >C=CH-N<, >N-CH=C<, >C=N-N< and >N-N=C< and the other radicals have the meanings defined in the following specification. The compounds of formula I are leukotriene antagonists. The invention also provides pharmaceutically acceptable salts of the formula I compounds; pharmaceutical compositions containing the formula I compound, or their salts, for use in the treatment of, for example, allergic or inflammatory diseases, or endotoxic or traumatic shock conditions; and processes for the manufacture of the formula I compounds, as well as intermediates for use in such manufacture.
本发明提供了一系列式 I 的新型杂脂肪族羧酰胺,其中基团 >Z-Y-XC=CH-NN-CH=CC=N-NN-N=C<和其他基团具有以下说明书中定义的含义。式 I 的化合物是白三烯拮抗剂。本发明还提供了式 I 化合物的药学上可接受的盐;含有式 I 化合物或其盐的药物组合物,用于治疗例如过敏性或炎症性疾病,或内毒素性或创伤性休克病症;以及式 I 化合物的制造工艺和用于此类制造的中间体。
US5041460A
申请人:——
公开号:US5041460A
公开(公告)日:1991-08-20
Heter-aliphatic carboxamides
申请人:ICI Americas Inc.
公开号:US05041460A1
公开(公告)日:1991-08-20
This invention provides a series of novel heter-aliphatic carboxamides of formula I in which the group >Z--Y--X< is selected from >C.dbd.CH--N<, >N--CH.dbd.C<, >C.dbd.N--N< and >N--N.dbd.C< and the other radicals have the meanings defined in the following specification. The compounds of formula I are leukotriene antagonists. The invention also provides pharmaceutically acceptable salts of the formula I compounds; pharmaceutical compositions containing the formula I compound, or their salts, for use in the treatment of, for example, allergic or inflammatory diseases, or endotoxic or traumatic shock conditions; and processes for the manufacture of the formula I compounds, as well as intermediates for use in such manufacture.